STOCK TITAN

Edwards Lifesciences (EW) Financials

EW NYSE
Trailing 12 months to September 30, 2026
Revenue $6.7B +13.4% YoY
Net Income $1.0B -25.3% YoY
EPS (Diluted) $1.77 -23.7% YoY
Free Cash Flow $1.4B +77.1% YoY
Market Cap $60.6B as of Nov 17, 2026
Price / Sales 9.1x on $6.7B revenue, trailing 12 months to September 30, 2026
Price / Earnings 59.4x on $1.0B net income, trailing 12 months to September 30, 2026
Price / Book 5.6x on $10.9B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EW SEC filings page.

Edwards Lifesciences Corp (EW) reported $6.7B in revenue over the twelve months to Sep 30, 2026, up 13.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EW FY2025

FY2025 shows a growing, lightly indebted business where expanding sales are being absorbed by costs faster than they become operating profit.

FY2025 paired revenue growth of 11.5% with an operating-income decline of 8.3%, showing a sales-to-profit disconnect as additional volume failed to translate into operating earnings. SG&A reached $2.09B and 34.4% of revenue, making expense absorption—rather than demand volume—the clearest pressure point.

Operating cash flow rebounded from $542M in FY2024 to $1.60B in FY2025 even as net income fell, so the latest year’s cash conversion is materially stronger than the prior year’s accounting result. The 148.6% operating-cash-flow-to-net-income ratio alongside $1.34B of free cash flow indicates that reported profit remained cash after investment.

Debt was $598M against liabilities equal to 24.5% of assets in FY2025, describing a balance sheet not primarily funded by borrowing. Capital expenditures were $260M, or 4.3% of revenue, so cash generation recovered without a larger reinvestment share than in prior reported years.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 72 / 100
Financial Health Score 72/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Edwards Lifesciences Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
38

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Edwards Lifesciences Corp scores 38/100 on it among other operating companies.

Growth
65

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Edwards Lifesciences Corp scores 65/100 on it among other operating companies.

Leverage
93

Edwards Lifesciences Corp held more cash than long-term debt at the end of fiscal year 2025, with $2.9B of cash against $598.3M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Edwards Lifesciences Corp scores 93/100 among other operating companies measured the same way.

Liquidity
85

Edwards Lifesciences Corp held $3.72 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.72. Liquidity ranks operating companies on that ratio, and Edwards Lifesciences Corp scores 85/100 among other operating companies.

Cash Flow
78

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Edwards Lifesciences Corp scores 78/100 on it among other operating companies.

Returns
73

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Edwards Lifesciences Corp scores 73/100 on it among other operating companies.

Altman Z-Score Safe
13.46

Edwards Lifesciences Corp scores 13.46, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $60.6B against total liabilities of $3.4B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
6/9

Edwards Lifesciences Corp passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.49x

For every $1 of reported earnings, Edwards Lifesciences Corp generates $1.49 in operating cash flow ($1.6B OCF vs $1.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
61.97x

Edwards Lifesciences Corp earns $61.97 in operating income for every $1 of interest expense ($1.3B vs $20.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.7B
YoY+10.5%
QoQ-1.5%
5Y CAGR+5.5%
10Y CAGR+8.8%

Edwards Lifesciences Corp generated $1.7B in revenue in Q3 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is down 1.5%.

EBITDA
$344.0M
YoY-0.7%
QoQ-38.1%

Edwards Lifesciences Corp's EBITDA was $344.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.7% from the same quarter a year earlier. Against the prior quarter it is down 38.1%.

Net Income
$307.5M
YoY+5.6%
QoQ+27.1%
5Y CAGR-2.0%
10Y CAGR+8.1%

Edwards Lifesciences Corp reported $307.5M in net income in Q3 2026. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is up 27.1%.

EPS (Diluted)
$0.53
YoY+6.0%
QoQ+26.2%
5Y CAGR-0.4%
10Y CAGR+9.4%

Edwards Lifesciences Corp earned $0.53 per diluted share (EPS) in Q3 2026. This represents an increase of 6.0% from the same quarter a year earlier. Against the prior quarter it is up 26.2%.

Cash & Balance Sheet

Free Cash Flow
$506.7M
YoY-1.8%
QoQ-13.4%
5Y CAGR+1.5%
10Y CAGR+12.4%

Edwards Lifesciences Corp generated $506.7M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 13.4%.

Cash & Debt
$3.1B
YoY+15.8%
QoQ+7.0%
5Y CAGR+15.6%
10Y CAGR+17.0%

Edwards Lifesciences Corp held $3.1B in cash against $598.8M in long-term debt as of Q3 2026.

Shares Outstanding
575M
YoY-0.9%
QoQ-0.2%
5Y CAGR-1.6%
10Y CAGR-1.1%

Edwards Lifesciences Corp had 575M shares outstanding in Q3 2026. This represents a decrease of 0.9% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
78.5%
YoY+0.7pp
QoQ+1.0pp
5Y change+2.3pp
10Y change+5.7pp

Edwards Lifesciences Corp's gross margin was 78.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.

Operating Margin
17.4%
YoY-2.3pp
QoQ-12.0pp

Edwards Lifesciences Corp's operating margin was 17.4% in Q3 2026, reflecting core business profitability. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.0 percentage points.

Net Margin
17.9%
YoY-0.8pp
QoQ+4.0pp
5Y change-8.0pp
10Y change-1.2pp

Edwards Lifesciences Corp's net profit margin was 17.9% in Q3 2026, showing the share of revenue converted to profit. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.

Return on Equity
2.8%
YoY0.0pp
QoQ+0.5pp
5Y change-3.3pp
10Y change-2.4pp

Edwards Lifesciences Corp's quarterly ROE was 2.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Capital Allocation

R&D Spending
$281.4M
YoY+0.2%
QoQ+0.9%

Edwards Lifesciences Corp invested $281.4M in research and development in Q3 2026. This represents an increase of 0.2% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Share Buybacks
$138.9M
YoY-76.4%
QoQ-9.4%
5Y CAGR+138.5%
10Y CAGR+92.4%

Edwards Lifesciences Corp spent $138.9M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 76.4% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.

Capital Expenditures
$63.6M
YoY+10.6%
QoQ-4.9%
5Y CAGR+0.9%
10Y CAGR+2.8%

Edwards Lifesciences Corp invested $63.6M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 10.6% from the same quarter a year earlier. Against the prior quarter it is down 4.9%.

EW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EW quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.7B+10.5%$1.7B+13.6%$1.6B+16.7%$1.6B+13.3%$1.6B+14.7%$1.5B+11.9%$1.4B+6.2%$1.4B+9.4%
Cost of Revenue$369.2M+7.0%$392.4M+13.9%$362.6M+20.2%$343.0M$345.2M+31.3%$344.4M+25.0%$301.6M+5.1%N/A
Gross Profit$1.3B+11.5%$1.3B+13.5%$1.3B+15.7%$1.2B+12.2%$1.2B+10.7%$1.2B+8.6%$1.1B+6.5%$1.1B+7.7%
R&D Expenses$281.4M+0.2%$278.9M+1.0%$263.3M+3.4%$267.7M$280.7M+10.8%$276.2M+1.6%$254.6M-0.8%N/A
SG&A Expenses$560.9M+9.0%$561.2M+11.8%$522.2M+12.1%$602.9M$514.6M+22.1%$502.0M+12.2%$465.7M+8.7%N/A
Operating Income$299.1M-2.6%$513.2M+24.8%$477.6M+21.0%$151.1M$307.1M-12.4%$411.2M+12.2%$394.8M+13.1%N/A
EBITDA$344.0M-0.7%$555.9M+23.7%$518.5M+20.2%$193.8M$346.3M-10.1%$449.3M+10.6%$431.4M+11.3%N/A
Income Tax$61.8M+10.2%$278.4M+333.0%$78.3M+11.4%$26.2M$56.1M+37.8%$64.3M+221.5%$70.3M+51.8%N/A
Net Income$307.5M+5.6%$241.9M-27.4%$380.7M+6.3%$91.2M-76.3%$291.1M-90.5%$333.2M-9.0%$358.0M+1.7%$385.6M+4.2%
EPS (Basic)$0.53+6.0%$0.42-26.3%$0.66+8.2%$0.16-75.4%$0.50-90.3%$0.57-6.6%$0.61+5.2%$0.65+6.6%
EPS (Diluted)$0.53+6.0%$0.42-25.0%$0.66+8.2%$0.16-75.4%$0.50-90.3%$0.56-8.2%$0.61+5.2%$0.65+6.6%
Diluted Shares (Avg)578M-1.4%578M-1.8%581M-1.2%N/A586M-2.1%588M-2.7%588M-2.7%N/A

Not reported in any period shown, so not listed: Interest Expense.

EW Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EW quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$14.1B+6.6%$13.9B+2.8%$13.3B+2.3%$13.7B+4.9%$13.3B+2.3%$13.5B+33.6%$13.0B+33.7%$13.1B+39.4%
Current Assets$7.2B+14.0%$6.8B+3.7%$6.2B+0.3%$6.7B+7.2%$6.4B-5.5%$6.6B+45.6%$6.2B+49.0%$6.3B+55.7%
Cash & Equivalents$3.1B+15.8%$2.9B-11.2%$2.4B-22.1%$2.9B-3.5%$2.7B-27.0%$3.3B+99.0%$3.1B+156.5%$3.0B+168.9%
Short-Term Investments$1.5B+32.6%$1.3B+70.5%$1.2B+61.8%$1.3B+38.4%$1.2B+50.2%$789.4M+128.6%$757.9M+60.2%$930.7M+86.0%
Inventory$1.2B+1.6%$1.1B-0.9%$1.1B+0.5%$1.1B+3.6%$1.1B+3.3%$1.1B+11.4%$1.1B-7.7%$1.1B+20.3%
Accounts Receivable$784.9M+13.2%$770.4M+10.5%$775.7M+15.9%$659.6M+8.3%$693.3M-3.2%$697.0M-10.4%$669.2M-18.2%$609.1M-21.0%
Long-Term Investments$262.6M-4.4%$244.1M-18.2%$285.6M+2.8%$278.6M-9.5%$274.7M-14.0%$298.5M-15.5%$277.9M-39.0%$307.9M-47.3%
Goodwill$2.0B+10.4%$2.0B+9.8%$1.8B+2.3%$1.8B-0.5%$1.8B+10.2%$1.8B+54.4%$1.8B+42.0%$1.8B+55.2%
Total Liabilities$3.2B+3.8%$3.1B+9.0%$3.0B+5.8%$3.4B+12.3%$3.1B-8.7%$2.9B+11.1%$2.8B+11.0%$3.0B+13.2%
Current Liabilities$1.6B-0.7%$1.5B+7.3%$1.4B+1.0%$1.8B+20.5%$1.6B-18.3%$1.4B+15.4%$1.4B+25.6%$1.5B+25.9%
Non-Current Liabilities$1.6B+8.6%$1.6B+10.6%$1.6B+10.4%$1.5B+3.9%$1.5B+4.5%$1.5B+7.2%$1.4B-0.2%$1.5B+2.7%
Long-Term Debt$598.8M+0.1%$598.7M+0.1%$598.5M+0.1%$598.3M+0.1%$598.2M+0.1%$598.0M+0.1%$597.8M+0.1%$597.7M+0.1%
Total Equity$10.9B+6.4%$10.6B+0.7%$10.3B+2.0%$10.3B+3.4%$10.2B+6.9%$10.5B+41.8%$10.1B+42.3%$10.0B+50.4%
Retained Earnings$15.2B+7.2%$14.9B+7.3%$14.6B+8.1%$14.2B+8.2%$14.1B+10.7%$13.9B+42.7%$13.5B+44.7%$13.2B+46.4%

EW Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EW quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$570.3M-0.6%$651.9M+124.6%$43.8M-84.4%$450.9Mn/m$573.7M+63.1%$290.2M-21.9%$280.4Mn/m-$127.5M-193.3%
Depreciation & Amortization$44.9M+14.5%$42.7M+12.1%$40.9M+11.7%$42.7M+0.2%$39.2M+13.6%$38.1M-3.8%$36.6M-4.9%$42.6M+16.1%
Stock-Based Compensation$46.0M+11.9%$42.2M+12.5%$45.4M+12.9%N/A$41.1M+16.8%$37.5M+0.5%$40.2M-9.9%N/A
Capital Expenditures$63.6M+10.6%$66.9M+35.7%$64.9M+15.9%$97.4M+95.6%$57.5M+10.8%$49.3M-42.3%$56.0M-14.2%$49.8M-43.6%
Free Cash Flow$506.7M-1.8%$585.0M+142.8%-$21.1M-109.4%$353.5Mn/m$516.2M+72.1%$240.9M-15.8%$224.4Mn/m-$177.3M-467.1%
Investing Cash Flow-$256.4Mn/m-$193.2Mn/m-$92.8M-208.8%-$198.3Mn/m-$427.8M-115.8%-$172.1M-237.9%$85.3M+35.2%-$576.7M-4190.1%
Financing Cash Flow-$100.8Mn/m-$300K-100.6%-$451.2Mn/m-$11.4M-139.9%-$740.1Mn/m$52.7Mn/m-$258.0M-518.2%$28.6Mn/m
Share Buybacks$138.9M-76.4%$153.3M+2687.3%$421.8M+63.1%$40.6M-59.4%$588.7M-34.7%$5.5M-96.5%$258.6M+129200.0%$100.1M-77.7%

Not reported in any period shown, so not listed: Dividends Paid.

EW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EW quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin78.5%+0.7pp77.5%-0.1pp78.0%-0.6pp78.1%-0.8pp77.8%-2.8pp77.5%-2.4pp78.6%+0.2pp78.9%-1.3pp
Operating Margin17.4%-2.3pp29.5%+2.6pp29.0%+1.0pp9.6%19.8%-6.1pp26.8%+0.1pp28.0%+1.7ppN/A
Net Margin17.9%-0.8pp13.9%-7.9pp23.1%-2.3pp5.8%-22.0pp18.7%21.8%-5.0pp25.3%-1.1pp27.8%-1.4pp
Return on Equity2.8%0.0pp2.3%-0.9pp3.7%+0.2pp0.9%-3.0pp2.9%-29.3pp3.2%-1.8pp3.5%-1.4pp3.9%-1.7pp
Return on Assets2.2%0.0pp1.7%-0.7pp2.9%+0.1pp0.7%-2.3pp2.2%-21.5pp2.5%-1.2pp2.8%-0.9pp2.9%-1.0pp
Current Ratio4.60+0.6x4.52-0.2x4.420.0x3.72-0.5x4.00+0.5x4.68+1.0x4.45+0.7x4.18+0.8x
Debt-to-Equity0.060.0x0.060.0x0.060.0x0.060.0x0.060.0x0.060.0x0.060.0x0.060.0x
Liabilities-to-Equity0.290.0x0.300.0x0.290.0x0.330.0x0.30-0.1x0.27-0.1x0.28-0.1x0.30-0.1x
Asset Turnover0.120.0x0.130.0x0.120.0x0.110.0x0.120.0x0.110.0x0.110.0x0.110.0x
FCF Margin29.5%-3.7pp33.6%+17.9pp-1.3%-17.2pp22.5%+35.3pp33.2%+11.1pp15.7%-5.2pp15.9%+24.8pp-12.8%-16.6pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Edwards Lifesciences Corp EW FY2025 $6.1B $1.1B 17.7% $60.6B 72/100
Boston Scientific Corporation BSX FY2025 $20.1B $2.9B 14.4% $62.4B 66/100
GE HealthCare Technologies Inc. GEHC FY2025 $20.6B $2.1B 10.1% $37.0B 57/100
Stryker Corporation SYK FY2025 $25.1B $3.2B 12.9% $120.9B 69/100
DexCom, Inc. DXCM FY2025 $4.7B $836.3M 17.9% $30.6B 74/100
Medtronic plc MDT FY2026 $36.4B $4.8B 13.2% $130.9B 63/100

Frequently Asked Questions

Edwards Lifesciences Corp (EW) reported $6.1B in total revenue for fiscal year 2025. This represents a 11.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Edwards Lifesciences Corp (EW) revenue grew by 11.5% year-over-year, from $5.4B to $6.1B in fiscal year 2025.

Yes, Edwards Lifesciences Corp (EW) reported a net income of $1.0B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.1B, with a net profit margin of 17.7%.

Edwards Lifesciences Corp (EW) reported diluted earnings per share of $1.83 for fiscal year 2025. This represents a -73.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Edwards Lifesciences Corp (EW) had EBITDA of $1.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Edwards Lifesciences Corp (EW) had $2.9B in cash and equivalents against $598.3M in long-term debt.

Edwards Lifesciences Corp (EW) had a gross margin of 78.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Edwards Lifesciences Corp (EW) had an operating margin of 20.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Edwards Lifesciences Corp (EW) had a net profit margin of 17.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Edwards Lifesciences Corp (EW) has a return on equity of 10.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Edwards Lifesciences Corp (EW) generated $1.3B in free cash flow during fiscal year 2025. This represents a 360.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Edwards Lifesciences Corp (EW) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Edwards Lifesciences Corp (EW) had $13.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Edwards Lifesciences Corp (EW) invested $260.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Edwards Lifesciences Corp (EW) invested $1.1B in research and development during fiscal year 2025.

Yes, Edwards Lifesciences Corp (EW) spent $893.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Edwards Lifesciences Corp (EW) had 581M shares outstanding as of fiscal year 2025.

Edwards Lifesciences Corp (EW) had a current ratio of 3.72 as of fiscal year 2025, which is generally considered healthy.

Edwards Lifesciences Corp (EW) had a debt-to-equity ratio of 0.06 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Edwards Lifesciences Corp (EW) had a liabilities-to-equity ratio of 0.33 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Edwards Lifesciences Corp (EW) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Edwards Lifesciences Corp (EW) trades at 59.4x earnings, its market capitalization divided by $1.0B net income, trailing 12 months to September 30, 2026. The market capitalization is $60.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Edwards Lifesciences Corp (EW) trades at 9.1x sales, its market capitalization divided by $6.7B revenue, trailing 12 months to September 30, 2026. The market capitalization is $60.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Edwards Lifesciences Corp (EW) has an Altman Z-Score of 13.46, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Edwards Lifesciences Corp (EW) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Edwards Lifesciences Corp (EW) has an earnings quality ratio of 1.49x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Edwards Lifesciences Corp (EW) has an interest coverage ratio of 61.97x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Edwards Lifesciences Corp (EW) scores 72 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top